IVERIC bio (ISEE) Reports In-Line Q1 EPS

Go back to IVERIC bio (ISEE) Reports In-Line Q1 EPS

Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results

May 4, 2022 6:32 AM UTC

- Zimura® GATHER2 Topline Data Expected in the Third Quarter of this Year-

- GATHER2 Trial Completion at 94% for Year One; Patient Retention Continues to Exceed Expectations with a Target 12-Month Injection Fidelity Rate of Greater than 90%

- U.S. Patent Covering Methods of Treating GA with Zimura Granted by USPTO

- Conference Call and Webcast Today, May 4, 2022, at 8:00 a.m. ET

PARSIPPANY, N.J.--(BUSINESS... More